Annual FCF
-$29.48 M
+$158.08 M+84.28%
December 31, 2023
Summary
- As of February 8, 2025, TBPH annual free cash flow is -$29.48 million, with the most recent change of +$158.08 million (+84.28%) on December 31, 2023.
- During the last 3 years, TBPH annual FCF has risen by +$227.53 million (+88.53%).
- TBPH annual FCF is now at all-time high.
Performance
TBPH Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly FCF
-$5.21 M
-$760.00 K-17.07%
September 30, 2024
Summary
- As of February 8, 2025, TBPH quarterly free cash flow is -$5.21 million, with the most recent change of -$760.00 thousand (-17.07%) on September 30, 2024.
- Over the past year, TBPH quarterly FCF has dropped by -$2.70 million (-107.86%).
- TBPH quarterly FCF is now -111.07% below its all-time high of $47.05 million, reached on March 31, 2018.
Performance
TBPH Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM FCF
-$12.31 M
-$2.70 M-28.16%
September 30, 2024
Summary
- As of February 8, 2025, TBPH TTM free cash flow is -$12.31 million, with the most recent change of -$2.70 million (-28.16%) on September 30, 2024.
- Over the past year, TBPH TTM FCF has increased by +$139.97 million (+91.92%).
- TBPH TTM FCF is now -28.16% below its all-time high of -$9.60 million, reached on June 30, 2024.
Performance
TBPH TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Free Cash Flow Formula
FCF = Cash From Operations − CAPEX
TBPH Free Cash Flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +84.3% | -107.9% | +91.9% |
| 3 y3 years | +88.5% | +88.8% | +94.8% |
| 5 y5 years | +75.5% | +92.1% | +95.2% |
TBPH Free Cash Flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +86.0% | -368.2% | +95.8% | -28.2% | +94.2% |
| 5 y | 5-year | at high | +88.5% | -368.2% | +95.8% | -28.2% | +95.5% |
| alltime | all time | at high | +88.5% | -111.1% | +95.8% | -28.2% | +95.5% |
Theravance Biopharma Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$5.21 M(+17.1%) | -$12.31 M(+28.2%) |
| Jun 2024 | - | -$4.45 M(+299.9%) | -$9.60 M(-47.9%) |
| Mar 2024 | - | -$1.11 M(-27.3%) | -$18.44 M(-37.5%) |
| Dec 2023 | -$29.48 M(-84.3%) | -$1.53 M(-38.9%) | -$29.48 M(-80.6%) |
| Sep 2023 | - | -$2.51 M(-81.1%) | -$152.28 M(-11.4%) |
| Jun 2023 | - | -$13.29 M(+9.3%) | -$171.85 M(-0.9%) |
| Mar 2023 | - | -$12.16 M(-90.2%) | -$173.40 M(-7.5%) |
| Dec 2022 | -$187.56 M(-11.2%) | -$124.32 M(+463.0%) | -$187.56 M(+76.7%) |
| Sep 2022 | - | -$22.08 M(+48.8%) | -$106.12 M(-18.7%) |
| Jun 2022 | - | -$14.84 M(-43.6%) | -$130.53 M(-21.3%) |
| Mar 2022 | - | -$26.32 M(-38.6%) | -$165.95 M(-21.4%) |
| Dec 2021 | -$211.26 M(-17.8%) | -$42.88 M(-7.8%) | -$211.26 M(-9.9%) |
| Sep 2021 | - | -$46.48 M(-7.5%) | -$234.56 M(-12.2%) |
| Jun 2021 | - | -$50.27 M(-29.8%) | -$267.15 M(-2.0%) |
| Mar 2021 | - | -$71.63 M(+8.3%) | -$272.60 M(+6.1%) |
| Dec 2020 | -$257.02 M(+6.5%) | -$66.17 M(-16.3%) | -$257.02 M(+0.2%) |
| Sep 2020 | - | -$79.08 M(+41.9%) | -$256.50 M(+15.5%) |
| Jun 2020 | - | -$55.71 M(-0.6%) | -$222.12 M(+3.3%) |
| Mar 2020 | - | -$56.05 M(-14.6%) | -$215.01 M(-10.9%) |
| Dec 2019 | -$241.37 M(+101.0%) | -$65.66 M(+46.9%) | -$241.37 M(+5.2%) |
| Sep 2019 | - | -$44.70 M(-8.0%) | -$229.40 M(-2.6%) |
| Jun 2019 | - | -$48.61 M(-41.0%) | -$235.55 M(-5.6%) |
| Mar 2019 | - | -$82.41 M(+53.5%) | -$249.57 M(+107.8%) |
| Dec 2018 | -$120.11 M | -$53.68 M(+5.6%) | -$120.11 M(+8.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2018 | - | -$50.85 M(-18.8%) | -$110.89 M(-10.0%) |
| Jun 2018 | - | -$62.63 M(-233.1%) | -$123.16 M(+16.4%) |
| Mar 2018 | - | $47.05 M(-205.8%) | -$105.79 M(-48.0%) |
| Dec 2017 | -$203.46 M(+101.2%) | -$44.46 M(-29.6%) | -$203.46 M(+8.5%) |
| Sep 2017 | - | -$63.13 M(+39.5%) | -$187.51 M(+36.6%) |
| Jun 2017 | - | -$45.26 M(-10.6%) | -$137.23 M(+10.0%) |
| Mar 2017 | - | -$50.61 M(+77.5%) | -$124.74 M(+23.4%) |
| Dec 2016 | -$101.12 M(-41.0%) | -$28.51 M(+122.0%) | -$101.12 M(-5.5%) |
| Sep 2016 | - | -$12.85 M(-60.8%) | -$106.96 M(-15.6%) |
| Jun 2016 | - | -$32.77 M(+21.4%) | -$126.78 M(-10.3%) |
| Mar 2016 | - | -$26.99 M(-21.4%) | -$141.33 M(-17.6%) |
| Dec 2015 | -$171.50 M(-3.8%) | -$34.35 M(+5.2%) | -$171.50 M(-5.0%) |
| Sep 2015 | - | -$32.66 M(-31.0%) | -$180.46 M(-2.3%) |
| Jun 2015 | - | -$47.32 M(-17.2%) | -$184.64 M(-2.3%) |
| Mar 2015 | - | -$57.17 M(+32.0%) | -$189.01 M(+6.0%) |
| Dec 2014 | -$178.26 M(+44.1%) | -$43.30 M(+17.6%) | -$178.26 M(+4.1%) |
| Sep 2014 | - | -$36.84 M(-28.7%) | -$171.21 M(+2.2%) |
| Jun 2014 | - | -$51.70 M(+11.4%) | -$167.55 M(+18.9%) |
| Mar 2014 | - | -$46.42 M(+28.0%) | -$140.88 M(+13.9%) |
| Dec 2013 | -$123.69 M(+1.6%) | -$36.25 M(+9.3%) | -$123.69 M(+41.5%) |
| Sep 2013 | - | -$33.17 M(+32.5%) | -$87.44 M(+61.1%) |
| Jun 2013 | - | -$25.04 M(-14.4%) | -$54.27 M(+85.6%) |
| Mar 2013 | - | -$29.23 M | -$29.23 M |
| Dec 2012 | -$121.70 M | - | - |
FAQ
- What is Theravance Biopharma annual free cash flow?
- What is the all time high annual FCF for Theravance Biopharma?
- What is Theravance Biopharma annual FCF year-on-year change?
- What is Theravance Biopharma quarterly free cash flow?
- What is the all time high quarterly FCF for Theravance Biopharma?
- What is Theravance Biopharma quarterly FCF year-on-year change?
- What is Theravance Biopharma TTM free cash flow?
- What is the all time high TTM FCF for Theravance Biopharma?
- What is Theravance Biopharma TTM FCF year-on-year change?
What is Theravance Biopharma annual free cash flow?
The current annual FCF of TBPH is -$29.48 M
What is the all time high annual FCF for Theravance Biopharma?
Theravance Biopharma all-time high annual free cash flow is -$29.48 M
What is Theravance Biopharma annual FCF year-on-year change?
Over the past year, TBPH annual free cash flow has changed by +$158.08 M (+84.28%)
What is Theravance Biopharma quarterly free cash flow?
The current quarterly FCF of TBPH is -$5.21 M
What is the all time high quarterly FCF for Theravance Biopharma?
Theravance Biopharma all-time high quarterly free cash flow is $47.05 M
What is Theravance Biopharma quarterly FCF year-on-year change?
Over the past year, TBPH quarterly free cash flow has changed by -$2.70 M (-107.86%)
What is Theravance Biopharma TTM free cash flow?
The current TTM FCF of TBPH is -$12.31 M
What is the all time high TTM FCF for Theravance Biopharma?
Theravance Biopharma all-time high TTM free cash flow is -$9.60 M
What is Theravance Biopharma TTM FCF year-on-year change?
Over the past year, TBPH TTM free cash flow has changed by +$139.97 M (+91.92%)